AU2007267928A1 - Methods and compositions using immunomodulatory compounds in combination therapy - Google Patents

Methods and compositions using immunomodulatory compounds in combination therapy Download PDF

Info

Publication number
AU2007267928A1
AU2007267928A1 AU2007267928A AU2007267928A AU2007267928A1 AU 2007267928 A1 AU2007267928 A1 AU 2007267928A1 AU 2007267928 A AU2007267928 A AU 2007267928A AU 2007267928 A AU2007267928 A AU 2007267928A AU 2007267928 A1 AU2007267928 A1 AU 2007267928A1
Authority
AU
Australia
Prior art keywords
amino
dione
pharmaceutically acceptable
acceptable salt
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007267928A
Other languages
English (en)
Inventor
Helen Brady
Kyle Chan
Laura Corral
Laure Moutouh De Parseval
Dominique Verhelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AU2007267928A1 publication Critical patent/AU2007267928A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2007267928A 2006-05-26 2007-05-24 Methods and compositions using immunomodulatory compounds in combination therapy Abandoned AU2007267928A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80860206P 2006-05-26 2006-05-26
US60/808,602 2006-05-26
PCT/US2007/012495 WO2007139939A2 (en) 2006-05-26 2007-05-24 Methods and compositions using immunomodulatory compounds in combination therapy

Publications (1)

Publication Number Publication Date
AU2007267928A1 true AU2007267928A1 (en) 2007-12-06

Family

ID=38606531

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007267928A Abandoned AU2007267928A1 (en) 2006-05-26 2007-05-24 Methods and compositions using immunomodulatory compounds in combination therapy

Country Status (11)

Country Link
EP (1) EP2023912A2 (es)
JP (1) JP2009538318A (es)
KR (1) KR20090014393A (es)
CN (1) CN101495111A (es)
AU (1) AU2007267928A1 (es)
CA (1) CA2652888A1 (es)
IL (1) IL195412A0 (es)
MX (1) MX2008014912A (es)
RU (1) RU2426542C2 (es)
WO (1) WO2007139939A2 (es)
ZA (1) ZA200809956B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097120A1 (en) * 2008-01-29 2009-08-06 Celgene Corporation Methods using immunomodulatory compounds for modulating level of cd59
CA2868302A1 (en) * 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
ES2754199T3 (es) * 2013-08-22 2020-04-16 Vanda Pharmaceuticals Inc Tricostatina A para el tratamiento del mieloma múltiple
CN105579101A (zh) 2013-08-22 2016-05-11 万达制药公司 癌症的治疗
JP2017511132A (ja) * 2014-03-26 2017-04-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法
WO2015175916A1 (en) * 2014-05-16 2015-11-19 Celgene Corporation Methods and compositions using 4-amino-2-(2,6 dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment of cancers
WO2023034504A1 (en) * 2021-09-01 2023-03-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN103393681B (zh) * 2002-05-17 2017-04-12 细胞基因公司 用于治疗和控制多发性骨髓瘤的方法及组合物
CN101108185A (zh) * 2002-10-24 2008-01-23 细胞基因公司 用于治疗、改变和控制疼痛的包含免疫调节化合物的组合物
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CN101966183A (zh) * 2003-12-02 2011-02-09 细胞基因公司 用于治疗和控制血红蛋白病和贫血病的方法和组合物
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation

Also Published As

Publication number Publication date
RU2426542C2 (ru) 2011-08-20
EP2023912A2 (en) 2009-02-18
JP2009538318A (ja) 2009-11-05
KR20090014393A (ko) 2009-02-10
MX2008014912A (es) 2008-12-10
RU2008151713A (ru) 2010-07-10
WO2007139939A2 (en) 2007-12-06
WO2007139939A3 (en) 2008-07-03
CA2652888A1 (en) 2007-12-06
CN101495111A (zh) 2009-07-29
IL195412A0 (en) 2009-08-03
ZA200809956B (en) 2010-07-28

Similar Documents

Publication Publication Date Title
US20080051431A1 (en) Methods and compositions using immunomodulatory compounds in combination therapy
AU2004296765B2 (en) Methods and compositions for the treatment and management of hemoglobinopathy and anemia
AU2008202638B2 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
AU2005304420A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
AU2007267928A1 (en) Methods and compositions using immunomodulatory compounds in combination therapy
CA2621368A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US20080199422A1 (en) Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
AU2014202561B2 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
AU2012201727B2 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
ZELDIS Patent 2477301 Summary
NZ550831A (en) 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione or CC-4047 for the treatment and management of myelodysplastic syndromes
EP1900369A1 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application